Novavax appoints VP of vaccine research

Feb. 2, 2006 — Novavax Inc., a Malverne, Pa., developer of products using micellar nanoparticle and other technologies, announced the appointment of Rick Bright to the newly created position of vice president of vaccine research. Bright will report to Rahul Singhvi, president and CEO.

Most recently, Bright was at the Centers for Disease Control (CDC) and Prevention in Atlanta where he worked in the influenza branch of the strain surveillance section as an immunologist and virologist and where he served as team leader of the antiviral drug program.

Previously he held the position of senior research scientist and project manager, vaccine and immunology programs at Altea Therapeutics, a biotech startup company in Atlanta, where he directed the development of a new generation of vaccines and improved delivery methods for vaccines.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.